University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Epidemiology

Epidemiology

2020

Acute Encephalopathy With Elevated CSF Inflammatory Markers
as the Initial Presentation of COVID-19
Shelli Farhadian
Laura R. Glick
Chantal B. F. Vogels
Jared Thomas
Jennifer Chiarella

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles
Part of the Epidemiology Commons

Authors
Shelli Farhadian, Laura R. Glick, Chantal B. F. Vogels, Jared Thomas, Jennifer Chiarella, Arnau CasanovasMassana, Jing Zhou, Camila Odio, Pavithra Vijayakumar, Bertie Geng, John Fournier, Santos Bermejo,
Joseph R. Fauver, Tara Alpert, Anne L. Wyllie, Cynthia Turcotte, Matthew Steinle, Patrick Paczkowski,
Charles Dela Cruz, Craig Wilen, Albert I. Ko, Sean MacKay, Nathan D. Grubaugh, Serena Spudich, and Lydia
Aoun Barakat

Farhadian et al. BMC Neurology
(2020) 20:248
https://doi.org/10.1186/s12883-020-01812-2

CASE REPORT

Open Access

Acute encephalopathy with elevated CSF
inflammatory markers as the initial
presentation of COVID-19
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Abstract
Background: COVID-19 is caused by the severe acute respiratory syndrome virus SARS-CoV-2. It is widely
recognized as a respiratory pathogen, but neurologic complications can be the presenting manifestation in a
subset of infected patients.
Case presentation: We describe a 78-year old immunocompromised woman who presented with altered mental
status after witnessed seizure-like activity at home. She was found to have SARS-CoV-2 infection and associated
neuroinflammation. In this case, we undertake the first detailed analysis of cerebrospinal fluid (CSF) cytokines during
COVID-19 infection and find a unique pattern of inflammation in CSF, but no evidence of viral neuroinvasion.
Conclusion: Our findings suggest that neurologic symptoms such as encephalopathy and seizures may be the
initial presentation of COVID-19. Central nervous system inflammation may associate with neurologic manifestations
of disease.
Keywords: COVID-19, SARS-CoV-2, Neuroinflammation

Background
The novel SARS-CoV-2 coronavirus first emerged in the
city of Wuhan, China in December 2019. The virus has
since led to the COVID-19 global pandemic, infecting
over 2 million people and resulting in over 150,000
deaths to date. SARS-CoV-2 is a Betacoronavirus: the
newest of seven strains of coronavirus known to infect
humans and the third strain known to cause severe
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disease. While the coronavirus family is widely recognized as respiratory pathogens causing symptoms of
upper and lower respiratory tract infection, there are few
reported cases of viral invasion into the central nervous
system.
Here, we report the clinical presentation and the
course of illness of a 78 year-old woman who presented
with altered mental status and seizure-like activity and
was found to have SARS-CoV-2 associated encephalopathy, with abnormalities in her cerebrospinal fluid (CSF).

Case presentation
A 78 year-old woman with a history of kidney transplant
on immunosuppression presented to our academic
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medical center with altered mental status and seizurelike activity in March 2020. The patient was observed at
home to have sudden-onset uncontrolled limb movements with ocular deviation followed by several minutes
of unresponsiveness. At her baseline, the patient lived
independently and had no previous diagnosis of dementia or confusion. However, 3 days prior to admission,
she was noted to have confusion and disorientation. In
addition, she was noted to have fever and nasal congestion for 2 days prior to admission. The patient was
known to be adherent with her medical care and medications including tacrolimus, mycophenolate mofetil,
and lisinopril.
Upon arrival the emergency department, the patient was
febrile to 100.7 F but was otherwise hemodynamically
stable. On neurological examination, she was noted to be
alert and oriented but intermittently confused. She
demonstrated bilateral tremor-like movements of the
upper and lower extremities without any evidence of
convulsions, repetitive movements or rigidity. She had
no sensory or motor deficits and her cranial nerve functions were intact. The complete blood count was notable for a pancytopenia with a white blood cell count of
1.8 103/μL, hemoglobin of 10.8 g/dL, hematocrit of
37.4% and platelets of 130 103/μL. Absolute neutrophil
count was 0.9 103/μL and absolute lymphocyte count
was 0.6 103/μL. The basic metabolic panel was notable
for normal serum electrolytes and stable renal function.
Alkaline phosphatase was slightly elevated to 139 U/L
but hepatic function was otherwise unremarkable.
Thyroid-stimulating hormone was elevated to 8.1 mIU/
L, but thyroxine (T4) was within normal limits. Tacrolimus level was 3.1 mcg/L (lower than therapeutic
range). Procalcitonin was 0.5 μg/L and her respiratory
viral panel was negative. Two sets of blood cultures did
not grow any organisms. Electrocardiogram showed
normal sinus rhythm. Chest X-ray (Fig. 1, left) did not
reveal any focal consolidation, pulmonary edema,
pleural effusion or pneumothorax.

The patient was admitted to the general medicine floor
for further work-up of her altered mental status. She
underwent an electroencephalogram (EEG) once at the
beginning of her hospital course that demonstrated mild
generalized slowing and a magnetic resonance imaging
(MRI) scan with contrast that revealed atrophy and
patchy periventricular and subcortical white matter
hyperintensities, which were interpreted as sequelae of
small vessel ischemic disease (Fig. 2).
She subsequently underwent lumbar puncture, which
revealed CSF that was clear in appearance with no xanthrochromia. The CSF analysis revealed 350 red cells/uL,
1 white blood cell/uL, 75% lymphocytes, 25% monocytes,
glucose 67 mg/dL and protein 43 mg/dL. The CSF herpes simplex virus and varicella zoster virus polymerase
chain reactions (PCR) were negative. The plasma cytomegalovirus and adenovirus testing were negative by
PCR, and serologies indicated prior Epstein-Barr virus
and Parvovirus B19 infection. On hospital day 3, the patient had persistent fevers and developed cough with
dyspnea requiring oxygen supplementation. A chest Xray revealed bilateral pulmonary infiltrate (Fig. 1, right).
She therefore underwent SARS-CoV-2 PCR testing using
a nasopharynx swab and was found to be positive. Sequencing of this SARS-CoV-2 isolate revealed a virus
similar to other SARS-CoV-2 circulating in the region
(https://nextstrain.org/ncov?s=USA/CT-Yale-009/2020).
Further investigation of the CSF was done following
the patient’s COVID-19 diagnosis. Inflammatory cytokines were measured in CSF and plasma using a multiplex cytokine assay. This patient’s CSF and plasma were
tested alongside CSF and plasma specimens obtained
from three healthy control volunteers: Female age 63,
Female age 45, and Male age 62. (Fig. 3). These control
samples were collected during the last year for unrelated
studies and were kept frozen until the current cytokine
assays, when they were run in parallel with this patient’s
sample. Levels of Interleukin-6 (IL-6), Interleukin-8 (IL8), and Interferon-gamma induced protein-10 (IP-10)

Fig. 1 Chest radiographs. Chest X-ray on admission (left) and on hospital day 13 (right), showing worsening bilateral infiltrates
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Fig. 2 MRI brain. MRI without contrast demonstrates generalized atrophy and patchy periventricular and subcortical white matter hyperintensities

appeared to be elevated in both CSF and plasma of this
patient compared to control, with a unique Monocyte
Chemoattractant Protein-1 (MCP-1) signature found
only in CSF and not plasma.
The patient’s CSF was next tested for the presence of
SARS-CoV-2 by several methods and was negative. First,
quantitative reverse transcriptase polymerase chain reaction was performed using the Centers for Disease Control SARS-CoV-2 assay. Sequencing of SARS-CoV-2 in
the CSF was then attempted using both targeted (tiled
PCR-amplicons) and unbiased (“shotgun” metagenomic)
approaches. From the targeted sequencing, 316,111
reads were generated from the sample and a total of 60
reads aligned to SARS-CoV-2, which was not above
background. From the unbiased sequencing approach,
about 40 million reads were generated and none aligned
to SARS-CoV-2 or any other respiratory pathogen. Finally, culturing of SARS-CoV-2 was attempted from the
CSF supernatant, and after 4 days of culture, SARS-CoV2 by PCR was not detected.
Table 1 summarizes the patient’s laboratory findings at
the time of diagnosis of COVID-19 and the follow-up
course. Based on the patient’s age and co-morbidities,
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Discussion and conclusions
This case highlights the potential for COVID-19 to
present with acute neurological symptoms in the absence of respiratory illness. It remains unknown whether
central nervous system (CNS) abnormalities observed
during COVID-19 are due to viral invasion into the
CNS, to damage induced by SARS-CoV-2 induced inflammatory cytokines produced by immune cells within
and outside of the CNS, or to a generalized toxic-
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she met criteria for treatment initiation per our academic center treatment protocol. The patient received
hydroxychloroquine 400 mg twice daily for 1 day
followed by 200 mg twice daily for nine additional days.
Her confusion slowly improved. However, on hospital
day 13, she had worsening of her mental status and became hypoxemic, with chest X-ray showing worsening
bilateral infiltrates. She was therefore treated with the
IL-6 inhibitor, tocilizumab, with overall improvement in
her confusion and respiratory status. The patient was
able to be weaned off oxygen and discharged home
safely after 1 month of hospitalization. She remained in
good condition at the time of this case report.

Plasma

Fig. 3 Cytokine analysis of CSF and plasma. The COVID-19 patient showed a marked increase of a variety of inflammatory cytokine and
chemokines in CSF and plasma compare to three control subjects including IL-17A, IL-6, IL-8, IP-10, with a unique MCP-1 signature identified in
COVID-19 CSF. All samples were run in duplicate. Mean +/− SD.s
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Table 1 Blood laboratory values throughout the patient’s hospital course. Hydroxychloroquine was given day 3 and tocilizumab was
given on day 10, as shown
Day 3

Day 4

Day 5

Day 6

Day 7

Day 8

WBC

0.7

2.5

7.2

11.8

7.3

5.2
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-
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-

-
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-
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-
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Day 3: SARS-CoV-2 positive and start of hydroxychloroquine
Day 10: Tocilizumab given

metabolic encephalopathy associated with critical illness.
In this case, we undertook the first detailed analysis of
CSF cytokines during COVID-19 infection. We found
heightened inflammation in CSF and did not detect
SARS-COV-2 virus in the CSF. This patient received experimental therapy with hydroxychloroquine and tocilizumab. Hydroxychloroquine has recently been shown
to increase the risk for cardiotoxicity without discernable
anti-viral benefit, and it remains unknown whether tocilizumab is effective against COVID-19 [1].
Other coronaviruses (CoVs) have been demonstrated
to invade the CNS, infect neurons, and cause an influx
of inflammatory cytokines and immune cells in the CNS.
Human coronavirus OC43 (HCoV-OC43) has been
shown to infect neurons in vitro, and, in murine models,
to invade the CNS causing widespread neuronal damage
[2, 3]. Both SARS and MERS, the two other severe diseases caused by human CoVs, have been associated with
CNS manifestations [4, 5]. In the case of MERS, this was
associated with abnormal brain MRI findings of widespread, bilateral hyperintense lesions within the white
matter and subcortical areas, and with negative CSF
PCR for the MERS-CoV virus. The evidence for neuroinvasion of SARS-CoV-1 is stronger: SARS-CoV-1 has
been reported to invade the CNS in mice transgenic for
human ACE2 and was detected in human brain autopsy
specimens. Like SARS-CoV-1, SARS-CoV-2 infects human cells that express the ACE2 receptor, which is
expressed in neurons, leading to the hypothesis that
SARS-CoV-2 may invade the CNS [6, 7].
Emerging case reports and case series demonstrate evidence of neurological findings in a subset of patients
with COVID-19. Two observational series have reported
on the prevalence and spectrum of neurological disease
in hospitalized patients with COVID-19. A retrospective
case series from Wuhan, China analyzed 214 hospitalized patients from three different hospitals with a laboratory confirmed diagnosis of COVID-19. They found 78
of the 214 patients (36.4%) had central CNS, peripheral
nervous system or skeletal muscle symptoms. The most

common central nervous system findings were dizziness
(16.8%), and headache (13.1%). In those with severe
COVID-19 disease, 14.8% displayed encephalopathy [8].
In a case series reported from two centers in France, patients admitted to the hospital because of acute respiratory distress syndrome due to COVID-19 were similarly
noted to have high rates of neurological symptoms.
Twenty-six of 40 patients were noted to have confusion.
Similarly to the patient in this report, that case series
found no evidence for SARS-CoV-2 neuroinvasion by
PCR of CSF, and EEG findings were non-specific [9].
Isolated case reports have also emerged describing
cases of acute encephalopathy associated with COVID19, including a case of COVID-19-associated acute necrotizing encephalopathy, which is typically a postinfectious immune-mediated phenomenon [10]. To date,
there has been a single publication reporting possible
COVID-19-associated meningoencephalitis (presenting
as altered mental status in setting of new onset seizures)
in which SARS-CoV-2 was detected in CSF [11]. More
recent autopsy studies have detected low levels of SARSCoV-2 RNA in brain tissue in a subset (7 out of 22) of
patients who died with COVID-19 [12].
Our findings in this case suggest the possibility that
neurological symptoms in COVID-19 may be due to increased neuroinflammation rather than to CNS invasion
of virus, and that treatment of neurological complications
of COVID-19 may require targeting host-inflammation.
We found elevation of MCP-1 in CSF. This proinflammatory chemokine is expressed by numerous cell
types within the brain, including neurons, astrocytes, and
microglia, resulting in a recruitment of inflammatory infiltrate into the CNS [13]. MCP-1 is elevated in the CSF in
other neuroinflammatory and neuroinfectious disorders,
including multiple sclerosis, bacterial meningitis and HIV
infection [14–16]. CSF elevation of MCP-1 as well as
emerging reports of macrophage induced damage in lung
and other tissue suggest that specifically attenuating
monocyte-incurred damage during COVID-19 may prove
beneficial [17]. The findings in this single case should be
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followed up in further cases of seizure and encephalopathy
during COVID-19.
In summary, this case report illustrates neurological
disease as an initial presentation of COVID-19, in association with elevated inflammatory markers in CSF. The
underlying pathophysiology of neurological manifestations of COVID-19 remains incompletely understood
and deserves further investigation.
Abbreviations
CSF: Cerebrospinal fluid; PCR: Polymerase chain reaction; IL: Interleukin; IP10: IFN-γ-inducible protein 10; MCP-1: Monocyte Chemoattractant Protein-1;
CNS: Central nervous system; EEG: Electroencephalogram; CoVs: Coronavirus
Acknowledgements
None.
Authors’ contributions
SF and LB designed the study, acquired and interpreted the data, and have
agreed both to be personally accountable for the accuracy and integrity of
the entire work. LG and JT provided clinical care to the patient, performed
literature searches, interpreted the data, and drafted the manuscript. CV, JF,
AW, CW, TA, and NG collected, analyzed, and interpreted virological data
including sequencing and viral culture. JC, JZ, CT, MS, PP, and SM collected,
analyzed, and interpreted cytokine data. AK, SS, ACM, CO, PV, BG, JF, SB, and
CDC contributed to study design and conception, patient consent, and data
interpretation. All authors reviewed and revised the manuscript and
approved the final manuscript.
Funding
Dr. Farhadian is supported by NIH K23MH118999, the American Federation
for Aging Research, the Robert E. Leet and Clara Guthrie Patterson Trust. Dr.
Ko is supported by NIAID 5 R01 AI121207. This work was supported by the
Beatrice Kleinberg Neuwirth Fund. The funding bodies did not have roles in
the design of the study and data collection, analysis, and interpretation and
did not play any role in writing the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The patient was consented for participation in the COVID-19 IMPACT biorepository study at Yale, approved by the Yale University Institutional Review
Board, HIC#2000027690.
Consent for publication
The patient is aware of this case report submission and has provided written
consent for this publication.
Competing interests
The authors report no competing interests.
Author details
1
Department of Internal Medicine, Section of Infectious Diseases, Yale School
of Medicine, New Haven, CT 06510, USA. 2Department of Neurology, Yale
School of Medicine, New Haven, CT 06510, USA. 3Department of Internal
Medicine, Yale School of Medicine, New Haven, CT 06510, USA. 4Department
of Epidemiology of Microbial Diseases, Yale School of Public Health, New
Haven, CT 06510, USA. 5Isoplexis, Branford, CT 06540, USA. 6Department of
Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine,
Yale School of Medicine, New Haven, CT 06510, USA. 7Department of
Laboratory Medicine, Yale School of Medicine, New Haven, CT 06510, USA.

Received: 1 May 2020 Accepted: 1 June 2020

References
1. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational
study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl
J Med. 2020; NEJMoa2012410. https://doi.org/10.1056/NEJMoa2012410.
Online ahead of print.
2. Arbour N, Côté G, Lachance C, Tardieu M, Cashman NR, Talbot PJ. Acute
and persistent infection of human neural cell lines by human coronavirus
OC43. J Virol. 1999;73(4):3338–50.
3. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human
coronavirus OC43. Virology. 2003;315(1):20–33.
4. Arabi Y, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer A, et al. Severe
neurologic syndrome associated with Middle East respiratory syndrome
corona virus (MERS-CoV). Infection. 2015;43(4):495–501.
5. Wu Y, Xu X, Chen Z. Nervous system involvement after infection with
COVID-19 and other coronaviruses. Brain Behav Immun. 2020;S08891591(20):30357 Published online March 30, 2020.
6. Netland J, Meyerholz D, Moore S, Cassell M, Perlman S. Severe acute respiratory
syndrome coronavirus infection causes neuronal death in the absence of
encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75.
7. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, et al. Detection of severe acute
respiratory syndrome coronavirus in the brain: potential role of the
chemokine Mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089–96.
8. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological
manifestations of hospitalized patients with COVID-19 in Wuhan, China: a
retrospective case series study. JAMA Neurol. 2020;1:e201127.
9. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al.
Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;
382(23):2268–70. https://doi.org/10.1056/NEJMc2008597. Epub 2020 Apr 15.
10. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated
acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology.
2020;201187. https://doi.org/10.1148/radiol.2020201187. Online ahead of print.
11. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first
case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J
Infect Dis. 2020;94:55–8.
12. Puelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss
L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;
NEJMc2011400. https://doi.org/10.1056/NEJMc2011400. Online ahead of print.
13. Yao Y, Tsirka SE. Monocyte chemoattractant protein-1 and the blood-brain
barrier. Cell Mol Life Sci. 2014;71:683–97.
14. Weiss JM, Nath A, Major EO, Berman JW. HIV-1 tat induces monocyte
chemoattractant protein-1-mediated monocyte transmigration across a
model of the human blood-brain barrier and up-regulates CCR5 expression
on human monocytes. J Immunol. 1999;163(5):2953–9.
15. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple
sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin
Immunol. 2003;15:23–32.
16. Mastroianni CM, Lancella L, Mengoni F, Lichtner M, Santopadre P, D'Agostino
C, et al. Chemokine profiles in the cerebrospinal fluid (CSF) during the course
of pyogenic and tuberculous meningitis. Clin Exp Immunol. 1998;114:210–4.
17. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell Landscape of
Bronchoalveolar Immune Cells in Patients With COVID-19. Nat Med. 2020.
https://doi.org/10.1038/s41591-020-0901-9. Online ahead of print.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

